In­cyte cuts fi­nal tri­al for PI3K drug more than a year af­ter yank­ing ac­cel­er­at­ed ap­proval fil­ing

The “chal­leng­ing reg­u­la­to­ry land­scape” sur­round­ing the class of drugs known as PI3K in­hibitors has pushed In­cyte to shut down the fi­nal tri­al in its PI3K pro­gram.

In­cyte dis­closed in its first quar­ter up­date that it’s dis­con­tin­ued the de­vel­op­ment of parsaclis­ib in warm au­toim­mune he­molyt­ic ane­mia, for which it had kicked off a 100-pa­tient Phase III tri­al more than a year ago — one of six pro­grams that’s be­ing shelved in fa­vor of eight oth­er pro­grams that the biotech has de­cid­ed to fo­cus on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER